Company
Headquarters: Taipei City, Taiwan
TW$3.86 Billion
TWD as of Jan. 1, 2025
US$117.7 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $213.72 B |
| Stryker | $150.01 B |
| Boston Scientific Corporation | $149.80 B |
| Medtronic | $114.44 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Brighten Optix Corporation researches and develops, manufactures, and sells specialty contact lenses in Taiwan and the Asia Pacific region. The company offers its products under the Ortho-K myopia management lens, HiClear gas permeable (GP) lens, Briomoist lens care systems, SynergEyes hybrid lens, and Large Diameter GP lens. It also provides OEM/ODM collaboration services. The company is based in Taipei City, Taiwan.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Brighten Optix Corp has the following listings and related stock indices.
Stock: TWSE: 6747 wb_incandescent